Clin2
NCT07658339Possibly a fitNot yet recruiting

Testing an inhaled drug for COPD symptoms

COPD (Chronic Obstructive Pulmonary Disease)

Part of Lungs & breathing clinical trials.

This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
387 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You are between 40 and 80 years old.
  • You have been diagnosed with COPD and your lung function tests show moderate to severe airflow blockage (FEV1 between 30% and 80% of normal, and FEV1/FVC less than 0.7).
  • You often feel short of breath during daily activities (mMRC breathlessness score of 2 or higher).
  • You have not had a COPD flare-up requiring emergency treatment or hospitalization in the past 12 weeks.
  • You have not had a respiratory infection like a cold or pneumonia in the past 6 weeks.
  • You do not have other serious lung diseases (like asthma or tuberculosis), heart problems, or cancer that is not cured.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality
NCT07314242Not yet recruiting· Phase 2
Study of Hemay005 for moderate to severe COPD

This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.

Tianjin
NCT07634367Not yet recruiting· Phase 3
Long-term safety of HSK39004 inhaled medicine for COPD

This study tests whether a new inhaled medication called HSK39004 is safe and effective for people with moderate to severe COPD (a lung disease that makes breathing difficult). You would use this medicine regularly over a long period and have your lung function and symptoms checked.

Nanchang, Jiangxi
NCT07285122Recruiting· Phase 1
Inhaled study drug for healthy smokers and people with COPD

This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.

Nedlands, Western Australia
NCT07351734Recruiting· Phase 2
Testing JKN2403 for COPD: a new treatment option

This study tests an experimental drug called JKN2403 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve breathing compared to a placebo (a dummy pill).

Guangzhou, Guangdong
NCT07035652Not yet recruiting· Phase 1
Testing XH-S004 tablets for COPD over multiple doses

This trial tests an experimental tablet called XH-S004 for people with moderate-to-severe COPD. It looks at how safe the drug is, how the body processes it, and if it helps symptoms.

Beijing, Beijing Municipality

Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.